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Abstract: Rapid advances in genetic research have resulted
in the mass production of genetic data as well as the
emergence of public and private genetic databases that
disseminate this data to the public. The increase in access to
genetic information has resulted in advanced understanding
of disease epidemiology and treatment; however, it also
presents a new threat to the genetic privacy of individuals.
This paper discusses the current federal and state regulations
that control disclosure of genetic information for research
purposes. Specifically, HIPAA and the federal Common Rule
are analyzed as well as their impact on genetic research. In
addition, this paper discusses the emergence of biobanks and
the lack of federal regulation addressing them. Lastly, this
paper examines the tension between stricter privacy
regulations specific to genetic research and the advancement
of science.
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I. INTRODUCTION
Rapid advances in scientific research have spawned a new threat
to privacy. Technological innovations provide researchers with the
means to sequence entire genomes and publicly disseminate the data
through private and public genetic databases. These technological
advances pose a threat to the privacy of genetic information for
individuals who either directly or indirectly participate in genetic
research, raising a number of ethical issues that federal legislation has
failed to address.
Current federal legislation, which consists of the Health Insurance
Portability and Accountability Act of 1996 ("HIPAA") and the federal
Common Rule, fails to address the ethical concerns of genetic privacy.
The federal legislation is limited in its scope, allowing a large number
of researchers to evade both laws and further compromise the privacy
of an individual's genetic information. HIPAA demands compliance
only from institutions that are covered entities and that participate in
activities involving "protected health information" ("PHI"). Similarly,
the federal Common Rule is only applicable to institutions that receive
federal funding from an agency regulated by the Common Rule,
leaving a large portion of the private sector free from regulation.
The lack of a comprehensive federal scheme for protecting genetic
information has prompted a number of states to implement state laws
that aggressively address the ethical concerns of genetic privacy.' A
number of these state laws distinguish genetic information from other
health information, making genetic information subject to stricter
guidelines than those imposed on general medical information.
This paper first provides a comprehensive overview of federal
legislation, focusing on HIPAA and the Common Rule, the two major
regulatory schemes that address the privacy of genetic material.
Further, this paper discusses how both HIPAA and the Common Rule
grant genetic information only limited protection because research
institutions can avoid compliance by classifying themselves as non-
covered entities or by rejecting federal funding from any agency
regulated by the Common Rule. The federal government has failed to
implement legislation that specifically addresses genetic privacy,
thereby affording genetic information protection only if it is identified
1 See Nat'l Cancer Inst., 5o-State Survey of Human Tissue Regulation,
http://www.cancerdiagnosis.nci.nih.gov/specimens/5o statesurvey/analysis2.htm (last
visited Jan. 26, 2009) (provides analysis of current state genetic laws).
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as "PHI" or the genetic research is funded by a federal agency that
accepted compliance under the Common Rule.
Secondly, this paper provides a survey on state legislation that
implements stricter regulations regarding genetic material. A number
of states have passed legislation specifically addressing the privacy of
genetic information. In most of these states, genetic information is
subject to more stringent regulation than under federal laws. Many of
these state laws require researchers to obtain informed consent from
research participants, allowing researchers to use genetic material
only in the manner provided by the consent.
In addition to providing an overview of state and federal law, this
paper addresses the impact of genetic databases on genetic privacy
and proposed methods to resolve the existing tension between genetic
privacy and the continuing advancement of science. The Internet has
provided a means for the collection and dissemination of an enormous
amount of genetic data; however, proposed federal legislation has
made no attempt to regulate the privacy of this genetic information. A
number of methods have been proposed to address this emerging
concern, such as masking, collecting, and disseminating material only
from individuals giving explicit consent, and regulating genetic
material under federal legislation. The method receiving the most
widespread endorsement is to bring genetic material under federal
regulation, which provides privacy to individuals while still furthering
scientific advancement.
II. OVERVIEW OF FEDERAL REGULATIONS FOR GENETIC RESEARCH
A. THE HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT
OF 1996 AND ITS IMPACT ON RESEARCH
The Health Insurance Portability and Accountability Act of 1996
("HIPAA") requires standardization of a patient's electronic health,
administrative and financial data.2 It also provides security and
privacy standards for PHI.3 PHI is "individually identifiable health
information, held or maintained by a covered entity or its business
associates acting for the covered entity that is transmitted or
3 45 C.F.R. § 16o.103 (2007); 45 C.F.R. § 164.502 (2001).
2 Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 104-191, 110
Stat. 1936.
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maintained in any form or medium."4 Health information includes
any information, whether oral or recorded in any form, that "relates to
the past, present, or future physical or mental health or condition of
an individual; the provision of health care to an individual; or the
past, present, or future payment for health care to an individual."5
1. HIPAA's IMPACT ON MEDICAL AND SCIENTIFIC RESEARCH
Medical and scientific research is most directly affected by the
Privacy Rule implemented by HIPAA. The section of HIPAA relating
to medical and scientific research "establishes conditions under which
PHI can be used within an institution and disclosed to others outside
it; grants individuals rights regarding their PHI; and requires that
institutions maintain the privacy and security of PHI."6 Compliance
with HIPAA guidelines is only mandated when the information
utilized in research is identifiable PHI. PHI is identifiable if it
includes one or more identifiers, such as a patient's name, a
geographic subdivision smaller than a state, dates associated with a
patient or other identifying numbers.7
In general, the HIPAA Privacy Rule allows for a covered entity8 to
use and disclose PHI for research if it is authorized to do so by the
research subject in accordance with the guidelines outlined in the
Rule.9 For example, a valid HIPAA Privacy Rule authorization can
include a signed statement by the research subject that grants
permission to a covered entity to disclose PHI to a specified
4 45 C.F.R. § 16o.103; see also Dep't of Health & Hum. Servs., Protecting Personal Health
Information in Research: Understanding the HIPAA Privacy Rule,
http://privacyruleandresearch.nih.gov/pr o2.asp (last visited Jan. 26, 2009).
5 45 C.F.R. § 16o.103.
6 45 C.F.R. § 16o (2007); 45 C.F.R. § 164 (2007); see also YALE UNIV. SCH. OF MED., YALE
UNIVERSITY RESEARCHERS' GUIDE TO HIPAA PRIVACY: HEALTH INSURANCE PORTABILITY
AND ACCOUNTABILITY ACT OF 1996 HANDBOOK,
http://www.med.yale.edu/hic/hipaa/guide/index.html#hipaa (last visited Jan. 26, 2009).
7 YALE UNIV. SCH. OF MED., supra note 6; see also 45 C.F.R. § 164.502.
8 The covered entities to which HIPAA are applicable are health plans, health care
clearinghouses, and health care providers that routinely handle protected health
information. 45 C.F.R. § 164.103.
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recipient.'0 An authorization obtained for research purposes must
specifically state the research study that the PHI will be used for and
cannot authorize use of the PHI for non-specific or future research.",
When the covered entity, pursuant to an authorization, discloses PHI
to another covered entity, the Privacy Rule continues to apply.
However, if the recipient is a non-covered entity, the Privacy Rule
does not protect the PHI once disclosed.12
Alternatively, disclosure of PHI for research purposes by a covered
entity can occur without authorization if there is a waiver of
authorization. This can happen if the disclosure is approved by an
institutional review board ("IRB") protocol; if there is a limited data
set that is subject to a data use agreement; if the information is used
in preparatory research; or if the data is deidentified.13
A researcher can make a request to an institution's IRB to have
authorization waived even when the research involves PHI. A waiver
of authorization is available only in a limited number of
circumstances, such as when research cannot be practicably
conducted without the waiver or without access to the PHI. In order
to receive a waiver of authorization:
The researcher must provide written assurance to the
IRB that the PHI will not be re-used or disclosed, that
the use(s) and/or disclosure(s) of the PHI will be
limited to the minimum necessary standard, and that
the use(s) and/or disclosure(s) involve no more than
minimal privacy risk to the subjects.14
Researchers can also utilize PHI without authorization when the
research uses a limited data set or is used in preparatory research.'5 A
1o 45 C.F.R. § 164.5o8 (2007).
11Id
.
12 Id.
13 45 C.F.R. § 164.512 (2007); 45 C.F.R. § 164.514 (2007). "Deidentified protected health
information includes health information that does not identify an individual and with
respect to which there is no reasonable basis to believe that the information can be used to
identify an individual." 45 C.F.R. § 164.514 (2007).
14 45 C.F.R. § 164.512; see also YALE UNIV. SCH. OF MED., supra note 6.
15 45 C.F.R. § 164.514.
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limited data set contains a small number of identifiers and presents
only a minimal potential of identifying the individual with whom the
identifiers are associated. 16 The use of limited data sets is restricted to
research and to public health or health care operations. 17 Preparatory
research access "is limited to a review of data to assist in formulating a
hypothesis, determining the feasibility of conducting the study,
determining cell size, or other similar uses that precede the
development of an actual protocol." 8
Academic institutions can completely exempt research sectors of a
university from HIPAA regulation by electing to classify the university
as a "hybrid entity.'19 A university may qualify as a hybrid entity when
a single entity performs activities that include both covered and
uncovered functions.20 The university must designate the areas of the
institution that conduct electronic transactions of PHI as covered
entities.21 All other areas that are not involved in the transaction of
PHI will be identified as non-covered entities. The covered entities
(most often university hospitals) must comply with the Privacy Rule,
whereas the non-covered entities (most often research laboratories)
do not.
2. HIPAA's LIMITED IMPACT ON GENETIC INFORMATION
Genetic information has become one of the greatest research tools
available in determining disease epidemiology and promoting
treatment. Genetic information used daily in scientific research
contains intimate and personal information, which raises major
privacy concerns. The federal government, however, has failed to
address or provide special privacy protection for genetic information
in the context of genetic research.22
I6M.
17Id.
18 45 C.F.R. § 164.512; see also YALE UNIV. SCH. OF MED., supra note 6.
19 45 C.F.R. § 164.103 (2007); 45 C.F.R. §164.105 (2007).
20 45 C.F.R. § 164.103.
2145 C.F.R. § 164.105.
22 See, e.g., Genetic Information Nondiscrimination Act of 2oo8, Pub. L. No. 110-233, 122
Stat. 881 (prohibits U.S. insurance companies and employers from discriminating on the
basis of information derived from genetic tests).
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Only covered health care entities that deal with genetic
information are required to comply with the HIPAA regulations.23
These covered entities include providers of general medical services
that create or receive genetic information, as well as individuals that
provide genetics services, including the administration and
interpretation of genetic tests. This may mean that genetic
information generated and compiled in a research setting will be
excluded from HIPAA regulations because the researchers that
generate the genetic information are not covered entities. Under the
current version of HIPAA, genetic information used in research is only
protected if the researcher is characterized as a covered health care
provider or employed by an institution that is regulated by the HIPAA
provisions.
If genetic information falls within the scope of current HIPAA
privacy regulation, it will be afforded the same protection as other
health care information under HIPAA; thus, it can be disclosed for
treatment, payment, and other health care operations only after the
patient gives written consent of such disclosure.24
B. THE FEDERAL COMMON RULE AND ITS APPLICABILITY TO HUMAN
RESEARCH
The Common Rule is a federal policy regarding the protection of
human subjects, and it applies to research funded by a number of
federal agencies.25 It requires an IRB to review proposed research, the
researcher to obtain informed consent from the research subject, and
assurance by the research institution that it will comply with the
Common Rule regulations.26 HIPAA's requirements pertaining to
research do not replace or override the requirements of the federal
Common Rule.
The Common Rule only applies to research conducted or funded
by the federal agencies that have adopted it.27 Therefore, research
funded by a participating federal agency must comply with the
23 See 45 C.F.R. § 16o; 45 C.F.1. § 164.
2445 C.F.R. § 164.502 (2007).
2545 C.F.R. § 46.1O (2007).
26 45 C.F.R. § 46.103 (2007); 45 C.F.R. § 46.116 (2007).
27 45 C.F.R. § 46.101 (2007).
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regulations outlined in the Common Rule. Alternatively, federal law
does not demand compliance with the Common Rule when research is
conducted independent of federal funding from an agency that has
adopted the Common Rule.28
Researchers that receive funding from one of the federal agencies
that adopted the Common Rule must seek the approval of an IRB
before engaging in research with human subjects.29 A "human
subject" "includes human blood or tissue samples, as well as archival
medical information associated with the samples if the samples or
information, either directly or via coded identifiers, are linked to
individual donors."3o
In regard to collecting genetic information, institutions receiving
federal funding must abide by the Common Rule provisions because
genetic information is isolated from blood and tissue samples, both of
which are considered part of a "human subject" under the Common
Rule provisions. When research involves genetic testing, the federal
Office of Human Research Protections ("OHRP") recommends that
IRBs require investigators to inform subjects of potential risks,
including psychosocial risks that may arise from any breach of
confidentiality associated with the research.31
The Common Rule uses IRB review as the primary mechanism for
protecting human subjects and ensuring that adequate informed
consent is obtained prior to the start of a research project. Under the
Common Rule, all protocols involving human subjects must first be
approved by an institution's IRB.32 An IRB is not an accredited entity,
but it is required to meet certain membership requirements and
follow specified review procedures outlined in the Common Rule.33
Meaningful informed consent is fundamental to ensuring
protection of human research subjects. The Common Rule works to
ensure that meaningful informed consent is obtained by specifying
how informed consent should be documented, rather than focusing on
28 45 C.F.R. § 46.102 (2007).
29 45 C.F.R. § 46.1Ol (2007).
30 45 C.F.R. § 46.102 (2001).
31 See DEP'T OF HEALTH & HUM. SERVS., INST. REVIEW BD. GUIDEBOOK, CHAPTERV, SEC. H
(1993), http://www.hhs.gov/ohrp/irb/irb chapter5ii.htm.
32 45 C.F.R. § 46.109 (2007).
33 45 C.F.R. §§ 46.107-46.1o9.
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the process used to obtain it. To comply with the Common Rule, a
researcher needs to obtain informed consent (usually in writing) from
a research subject (or that subject's authorized representative) prior to
enrolling the subject in the research study.34
C. DISTINCTIONS BETWEEN THE PRIVACY RULE AND THE COMMON
RULE
The requirements of the HIPAA Privacy Rule are somewhat
different than the Common Rule in that HIPAA requires patient
authorization to release PHI (authorization is one of the four paths to
pursue research under HIPAA),35 whereas the Common Rule requires
informed consent prior to participation in research. Further, the
applicability of the two federal laws varies. The Privacy Rule requires
authorization for release of PHI for postmortem research,36 while the
Common Rule applies only to living individuals. 37 Because the
Common Rule and the Privacy Rule have different requirements for
what information must be "protected," researchers may have to meet
requirements of HIPAA, the Common Rule, both or none at all.
III. STATE LAWS IMPOSE HIGHER STANDARDS TO PROTECT PRIVACY OF
GENETIC INFORMATION
The lack of federal legislation regarding genetic information
prompted numerous states to pass laws that impose higher standards
for protection of genetic information. To date, twenty-nine states
have passed legislation that place restrictions on genetic tests and the
collection and disclosure of genetic information.38 These restrictions
have varying effects on genetic research, which depend upon the
definitions of "genetic information" and "genetic tests" and how
broadly these terms are defined in the legislation. The most restrictive
3445 C.F.R. § 46.116.
35 For a discussion of alternate paths, see infra Section V.A.
36 45 C.F.R. § 164.502 (2007).
37 45 C.F.R. §§ 46.101-102 (2007).
38 See NAT'L CONF. OF STATE LEGISLATURES, STATE GENETIC PRIVACY LAWS,
http://www.ncsl.org/programs/health/genetics/prt.htm (last visited Jan. 26, 2009)
(provides a list of state's genetic laws); see also Nat'l Cancer Inst., supra note 1.
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effect of these laws on research occurs when genetic testing is defined
so broadly as to include the most basic components of DNA.39
Among the states that have passed legislation regulating genetic
information, twenty-one states allow researchers to use genetic
information when specific conditions are met, with the most common
condition being protection of the patient's identity.40 This approach
differentiates between the use of tissue and data in the clinical setting
from use in the research setting, imposing less restrictive measures on
research activities.
Both Massachusetts and Nebraska laws use language that exclude
or limit the restrictions on the use of genetic information used for
research.41 For example, Massachusetts's statute describes genetic
information that is excluded from the restrictions implemented by the
statute, as information that is gathered from a clinical or diagnostic
test of DNA, RNA, or other genetic components: "The term genetic
information shall not include any information about an identifiable
person that is taken: (1) as a biopsy, autopsy, or clinical specimen
solely for the purpose of conducting an immediate clinical or
diagnostic test that is not a test of DNA, RNA, mitochondrial DNA,
chromosomes or proteins."42
Similarly, Nebraska's law excludes from the definition of genetic
test any activity conducted in accordance with biomedical research.43
Alternatively, Louisiana, New Hampshire, New Mexico, Oregon and
Iowa use broad language that includes research within the scope of
the statutes' definition of "genetic test.'44 Within these states, the use
of tissue samples, including those used in genetic research, is
governed by the restrictions set out in the states' laws.45
39 LA. REV. STAT. ANN. § 22: 213.7 (2007).
40 See NAT'L CONF. OF STATE LEGISLATURES, supra note 38; see also Nat'l Cancer Inst.,
supra note 1.
41 MASS. GEN. LAws ANN. ch. Ul, § 7oG (West 2000); NEB. REV. STAT. § 77-5519 (2007).
42 MASS. GEN. LAws ANN. ch. 111, § 7oG; see also Nat'l Cancer Inst., supra note 1.
43 NEB. REv. STAT. § 77-5519 (2005).
44 LA. REV. STAT. ANN. § 22:213.7 (2OO8); N.H. REv. STAT. ANN. § 141-H:l (2007); N.M.
STAT. ANN. § 24-21-2 (West 2005); OR. REv. STAT. §§ 192.531-192.549 (2007); IOWA CODE
§729.6 (2007).
45 See statutes, supra note 44.
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The variance in state law is not limited to the language used in the
legislation but also applies to the restrictions that are imposed by each
state's legislation. Twenty-seven states require informed consent46
from the individual providing the genetic material before the
information and/or material can be disclosed for research purposes,
with a subset of these states specifying the type of written
authorization required. 47 Within a number of states requiring
informed consent, specific provisions are included that regulate the
retention and future use of blood and tissue samples. For instance,
Michigan and Nebraska require that informed consent incorporate a
statement of future use of the sample and specify who will have access
to the sample. 48 New Jersey presents one of the strictest laws
regarding the use of genetic samples for research purposes. 49 It
requires all samples to be destroyed after completion of the research
project unless individual consent is obtained to retain the sample.5o
However, most states only require informed consent for use of genetic
data in research if the genetic material is identifiable and can be
linked to an individual.51
46 MICH. COMP. LAWS § 333.17520 (2008) ("Informed consent consists of a signed writing
executed by the test subject or the legally authorized representative of the test subject that
confirms that the physician or the individual acting under the delegatory authority of the
physician has explained, and the test subject or the legally authorized representative of the
test subject understands, at a minimum, all of the following: (a) The nature and purpose of
the presymptomatic or predictive genetic test; (b) The effectiveness and limitations of the
presymptomatic or predictive genetic test; (c) The implications of taking the
presymptomatic or predictive genetic test, including, but not limited to, the medical risks
and benefits; (d) The future uses of the sample taken from the test subject in order to
conduct the presymptomatic or predictive genetic test and the information obtained from
the presymptomatic or predictive genetic test; (e) The meaning of the presymptomatic or
predictive genetic test results and the procedure for providing notice of the results to the
test subject; (f) Who will have access to the sample taken from the test subject in order to
conduct the presymptomatic or predictive genetic test and the information obtained from
the presymptomatic or predictive genetic test, and the test subject's right to confidential
treatment of the sample and the information.").
47 See 45 C.F.R. § 164.5o8.
48 MICH. COMP. LAWS § 333.17520; NEB. REV. STAT. § 71-551 (2OO8).
49 N.J. STAT. ANN. § 10:5-46 (2002).
50 Id.
S ARK. CODE ANN. § 20-35-103 (2008); OKLA. STAT. tit. 36, § 3614.4 (2OO8).
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IV. THE HEIGHTENED CONCERN OF PRTVACY PERTAINING TO GENETIC
DATABASES
A. THE REASONS BEHIND THE HEIGHTENED CONCERN
Genetic databases consist of a collection of genetic and medical
information from a large number of people, arranged in a
systematically searchable way. Genetic databases have exploded in
popularity among researchers due to advances in scientific
technologies that allow for rapid sequencing of DNA at relatively little
cost. DNA sequencing produces enormous amounts of data that hold
great potential for use in determining disease epidemiology and
therapeutic treatments. Continuing advances in computer technology
mean that this abundant amount of genetic information can be stored,
analyzed and disseminated for public use. While the generation of
this genetic information holds great potential for treatment and
diagnosis of diseases, it also carries great risk to an individual's
privacy.52
Under current federal legislation, DNA sequences could
potentially be regulated by the Common Rule, which regulates all
federally funded research and sets forth federal policy concerning the
use of human subjects and HIPAA.53 However, the Common Rule will
not apply to DNA sequences unless the research utilizes human
subjects. Human subject research is defined under the Common Rule
as research involving "an individual about whom the investigator...
obtains data through intervention or interaction with the individual,
or identifiable private information."54
According to a guidance document published in 2004 by the
OHRP, data collected for a sequencing study is not subject to federal
regulation because the data is collected and coded by a primary
clinical investigator; the coded material is then provided to a
sequencing investigator who is prohibited from deciphering the code,
thus rendering the data unidentifiable.55 Likewise, HIPAA provides
52 Peter Gwynne & Gary Heebner, Advances in Genomics-Fresh Steps in Sequencing,
SCIENCE, June 10, 2005, http://www.sciencemag.org/products/gen-o6loo5.dtl#Systems.
53 45 C.F.R. § 46.1Ol (2007).
5445 C.F.R. § 46.102 (2007).
55Dep't of Health & Hum. Servs., Guidance on Research Involving Coded Private
Information or Biological Specimens, Aug. 10, 2004,
http://www.hhs.gov/ohrp/humansubjects/guidance/cdebiolo4.htm.
[Vol. 4:3
FENDRICK
little protection of genetic information obtained through DNA
sequencing due to the uncertainty of whether genomic data
constitutes identifiable PHI.
B. PROPOSED RESPONSES TO PROTECTING PRIVACY OF GENETIC
INFORMATION IN GENETIC DATABASES
Presently, privacy concerns about public release of genetic
information have been addressed by ensuring that disclosed
information is deidentified. However, the current measures may
prove to be inadequate for maintaining the privacy of genetic
information as databases continue to proliferate and technology
continues to advance and become more sophisticated. Scientists
admit that coded or deidentified sequenced DNA may be readily
linked to an individual as databases continue to expand in number
and sophistication.56 For example, a study in 2004 found that an
individual can be uniquely identified using a small number of genetic
markers when compared to a sample reference taken from the same
subject.57 The sample reference need not be a blood sample, but can
come from hair or other genetic material that may be surreptitiously
obtained.
Due to the lack of federal regulation of privacy issues pertaining to
genomic research, a number of alternative methods have been
proposed to address the furtherance of genetic research while still
maintaining an individual's right to privacy.58 One proposed method
56 Latanya Sweeney, Weaving Technology and Policy Together to Maintain
Confidentiality, 25 J.L. MED. & ETHICS 98 (1997); Bradley Malin & Latanya Sweeney, How
(not) to Protect Genomic Data Privacy in a Distributed Network: Using Trail Re-
identification to Evaluate and Design Anonymity Protection Systems, 37 J. BIOMEDICAL
INFO. 179 (2004); Nat'l Cancer Inst., Confidentiality, Data Security, and Cancer Research:
Perspectives from the National Cancer Institute, Mar. 23, 1999,
www3.cancer.gov/confidentiality.html.
57 Zhen Lin, Art Owen & Russ Altman, Genomic Research and Human Subject Privacy,
305 SCIENCE 183 (July 9, 2004), available at
http://www.sciencemag.org/cgi/content/full/sci;3o5/5681/183?maxtoshow=&HITS=lo&
hits=io&RESULTFORMAT=&fulltext=zhen+lin&searchid=I&FIRSTINDEX=o&resourcety
pe=HWCIT.
58 See Amy L. McGuire & Richard A. Gibbs, Genetics: No Longer De-Identified, 312
SCIENCE 371 (Apr. 6, 2oo6), available at
http://www.sciencemag.org/cgi/content/full/sci;312/5772/37o?maxtoshow=&HITS=lo&
hits= io&RESULTFORMAT=&fulltext=amy+mcguire+richard+gibbs&searchid= 1&FIRSTI
NDEX=o&resourcetype=HWCIT.
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is to implement a data access system that masks highly sensitive
data.59 A masking data access system provides electronic methods for
separating raw genetic data from personally identifiable
information. 60 The system prevents access to sensitive personal
information while still permitting access to the raw genetic material.
However, the data access system fails to address the tension
between the progression of genetic research and privacy, in that the
masking of personal data may render raw genetic material useless for
research. In particular, genetic research pertaining to epidemiology
requires access to information that goes beyond raw genetic material.
Advances in this field require that the raw genetic material be
accessed in conjunction with personal information (such as
background of familial diseases or disorders) to determine the
significance of a particular gene mutation and how this mutation
correlates with inheritable diseases.
Another proposed method to bridge the gap between scientific
progression and privacy of genetic information is to only seek out
individuals who agree to have their information publicly disclosed and
to provide those individuals with control over the dissemination of
their information.61 This option protects an individual's privacy, but,
unfortunately, threatens the progression of genetic research. With the
increasing threat of genetic discrimination, individuals will likely
become more concerned with dissemination of their genetic material
and will be less likely to voluntarily participate in genomic research
without the assurance of protection.62 In addition, this option may
present researchers with a biased set of genetic material. The genetic
information available to researchers would be only from individuals
willing to voluntarily participate, which may limit data to a specific set
of individuals and threaten the advancement of genetic research. 63
s9 Id.
60 Gabrielle Kohlmeier, The Risky Business of Lifestyle Genetic Testing: Protecting
Against Harmful Disclosure of Genetic Information, 11 UCLA J.L. & TECH. 2, 5 (2007).
61 Isaac S. Kohane & Russ B. Altman, Health Information Altruists-A Potentially Critical
Resource, 353 NEw ENG. J. MED. 2074, 2076 (2005).
62 Francis S. Collins & James D. Watson, Genetic Discrimination: Time to Act, 302
SCIENCE 745 (Oct. 31, 2003); Mark Rothstein, Expanding the EthicalAnalysis of Biobanks,
33 J.L. MED. & ETHICS 89 (2005).
63 Collins & Watson, supra note 62.
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A third and the most viable method to protect genetic information
is to bring genomic databases under the scope of federal regulations.
This can be accomplished either by identifying the research as human
subject research and thereby providing protection under the Common
Rule, or by providing protection to genomic data under HIPAA. To
protect genomic data under HIPAA, genetic information must be
specifically classified as PHI, which requires authorized consent or a
waiver of consent from the individual before the genetic material can
be used in research. By implementing a federal regulation that
specifically defines genomic information as regulated material, it will
foster public confidence in privacy; this may increase the willingness
of individuals to partake in genetic research, thereby enabling
scientific progress.
V. A GAP IN PRIVACY LAW: THE DANGER OF COMMERCIAL
DATABASES
Recently, a number of commercial biotech companies that collect
and store genetic information have emerged in the United States.
These privately held companies provide a variety of private services
and products including: paternity tests, genetic testing for
predisposition for certain diseases and traits, genealogy and the
tracing of origin, ancestry, and pharmacogenomics. 64 These
companies not only provide a service to the consumer, but also
provide profits to the company by compiling the consumer's sample
into a "biobank" that can be accessed by researchers for a fee. The
popularity of biobanks is rising due to economic incentives and the
lack of federal regulation of these databases.65
The Common Rule does not apply to the majority of biotech
companies because they are privately funded and do not receive
money from federal agencies. Similarly, whether HIPAA regulations
apply to these companies is questionable due to the uncertainty of
whether the privately held biobanks are categorized as covered
64 Examples of commercial companies running private biobanks include Genomics
Collaborative Inc., GolfStream Bioinformatics (formerly Ardais Corporation), 23andMe
and DNA Sciences, Inc.
65 See Yael Bregman-Eschet, Genetic Databases and Biobanks: Who Controls Our Genetic
Privacy?, 23 SANTA CLARA COMPUTER & HIGH TECH. L.J. i; Jocyeln Kaiser, Population
Databases Boom, From Iceland to the U.S., 298 SCIENCE 1158 (Nov. 8, 2002), available at
http://www.sciencemag.org/cgi/content/full/sci;298/5596/1i58?maxtoshow=&HITS=lO
&hits= lo&RESULTFORMAT=fulltext=kaiser+population+databases&searchid= 1&FIRS
TINDEX=oresourcetype=HWCIT.
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entities. 66 While it is clear that companies directly receiving genetic
material from consumers are not covered entities, and therefore, not
regulated by HIPAA, it is unclear whether companies that receive
samples from medical centers (which are covered entities) are
themselves covered entities under HIPAA. The privately held
companies may be considered business associates of the medical
center, providing limited protection to genetic material transferred
between the two institutions. 67 Business associates are not directly
required to comply with the Privacy Rule; instead, protection of
genetic information is achieved by a contract between the business
associate and the covered entity. 68 The contract should require that
the genetic information remain protected after disclosure to the
business associate. 69 However, if the information is deidentified by
the medical center, the biotech company will not be required to
comply with HIPAA even if the coding of the information is
reversible.7o
If states have failed to impose additional legislation, the lack of
federal regulation leaves biotech companies to self-regulate. This lack
of regulation also leaves individuals vulnerable to misuse of genetic
material submitted to a company for genetic testing and creates the
potential for public exposure of sensitive genetic material.71 Recently,
there have been state actions to limit activities of biobanks for non-
privacy reasons, usually because the testing is not being done in the
types of laboratories required by state law.72 Even if the non-privacy
issues are resolved, biobanks will continue to pose a threat to
individuals' privacy.
66 PEW INTERNET & AMERICAN LIFE PROJECT, EXPOSED ONLINE: WHY THE NEW FEDERAL
HEALTH PRIvACY REGULATION DOESN'T OFFER MUCH PROTECTION TO INTERNET USERS
(2001), http://www.pewinternet.org/pdfs/PIP-HPP-HealthPrivreport.pdf.
67 Id. at 1o.
68 id. at 16.
69/d.
70 45 C.F.R. § 164.502 (2007).
71 Misuse of genetic information may result in release of genetic information to third
parties through clinical records or disclosures that are compelled, both of which may result
in genetic discrimination. See Rothstein, supra note 62.
72 Andrew Pollack, California Licenses 2 Companies to Offer Gene Services, N.Y. TIMES,
Aug. 20, 2008, at C3, available at
http://www.nytimes.com/2oo8/o8/2o/business/2ogene.html?ref=health.
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VI. DANGERS TO RESEARCH VS. THE PRIVACY OF INDIVIDUALS
Genetic research provides researchers with invaluable information
that continues to foster progression in the study and treatment of
diseases. For example, the Human Genome Project has identified a
number of disease-causing genes, allowing for rapid diagnosis of
devastating diseases.73 Future research involving data compiled from
the Human Genome Project will permit scientists to study the disease-
associated genes and begin to develop therapies and cures for
numerous diseases. However, some of these studies will require
access to DNA data and to patients' corresponding medical history.
Researchers need the freedom to continue the Human Genome
Project and other beneficial genetic research without the hindrance of
privacy regulations. The Human Genome Project is just one example
of the many areas of genetic research that must be considered when
implementing privacy regulations that may threaten the progress of
research.
On the other hand, privacy advocates argue that genetic material
holds personal information that is the pathway into an individual's
past, present, and future by disclosing a person's traits, disease
patterns, and family history, and therefore, should be guaranteed
privacy.74 Many fear that without adequate protection, DNA collected
for genetic research will be used in a discriminatory manner. 75 For
example, health insurers could use genetic information to differentiate
premiums based on an individual's background.
Accordingly, while it is true that genetic information is personal
and needs protection, it is unnecessary to require more stringent
privacy laws for genetic information in areas where HIPAA, the
Common Rule and state laws adequately apply. When tissue and
genetic information are used in research regulated by state and federal
legislation, the individual is required to give informed consent or
authorization prior to the release of PHI for use in research. Current
legislation strikes the right balance between an individual's right to
73 See Nat'l Human Genome Research Inst., All About The Human Genome Project (HGP),
http://www.genome.gov/1ooo1772 (last visited Jan. 26, 2009).
74 GEORGE ANNAS, ET AL., THE GENETIC PRIvAcY Acr AND COMMENTARY (1995),
http://www.ornl.gov/hgmis/resource/privacy/privacyl.html; Michael M.J. Lin,
Conferring a Federal Property Right in Genetic Material: Stepping into the Future with
the Genetic Privacy Act, 22 AM. J.L. & MED. 109, 127-29 (1996).
75 See Nat'l Human Genome Research Inst., Genetic Discrimination,
http://genome.gov/1ooo2o77 (last visited Jan. 26, 2009).
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privacy and a researcher's right to advance genetic research. To
disturb the current balance by enforcing stricter regulation of genetic
information would hinder the ability of researchers to recruit
participants for research. On the other hand, loosening restrictions on
genetic research would compromise an individual's trust in the
confidentiality and privacy of their genetic information, making the
individual less likely to consent to the release or use of their genetic
information.
Nonetheless, further legislation must address those entities that
are not currently regulated by state or federal law, and are, therefore,
free to disseminate genetic material without informed consent or
authorization. These entities pose a significant threat to genetic
privacy.
VII. CONCLUSION
Genetic privacy is an emerging ethical concern that can best be
addressed by comprehensive federal legislation. Currently, federal
legislation leaves gaping holes that allow a number of researchers,
both in the private and public sectors, to conduct research without
consent or authorization. Many states have tried to close the holes in
federal legislation by imposing stricter laws for genetic privacy;
however, these laws are not uniform, and individuals are still exposed
to misuse of their genetic information.
Federal legislation should be amended to specifically identify
genetic material as PHI, but should not impose stricter regulations for
genetic material. Amending the legislation in this manner will reach a
balance that protects genetic privacy while still allowing research to
progress for the benefit of humanity.
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